Book contents
- The Clinical Use of Antipsychotic Plasma Levels
- Reviews
- The Clinical Use of Antipsychotic Plasma Levels
- Copyright page
- Half title page
- Contents
- Foreword
- Preface: How to Use This Handbook and Useful Tables for Handy Reference
- Introduction
- 1 Sampling Times for Oral and Long-Acting Injectable Agents
- 2 The Therapeutic Threshold and the Point of Futility
- 3 Level Interpretation Including Laboratory Reporting Issues, Responding to High Plasma Levels, Special Situations (Hepatic Dysfunction, Renal Dysfunction and Hemodialysis, Bariatric Surgery)
- 4 Tracking Oral Antipsychotic Adherence
- 5 What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability
- 6 Important Concepts about First-Generation Antipsychotics
- 7 Haloperidol and Haloperidol Decanoate
- 8 Fluphenazine and Fluphenazine Decanoate
- 9 Perphenazine and Perphenazine Decanoate
- 10 Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate
- 11 Chlorpromazine, Loxapine, Thiothixene, Trifluoperazine
- 12 Important Concepts about Second-Generation Antipsychotics
- 13 Clozapine
- 14 Risperidone Oral and Long-Acting Injectable; Paliperidone Oral and Long-Acting Injectable
- 15 Olanzapine and Olanzapine Pamoate
- 16 Aripiprazole, Aripiprazole Monohydrate, and Aripiprazole Lauroxil
- 17 Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine
- Appendix Therapeutic Threshold, Point of Futility, AGNP/ASCP Laboratory Alert Level, and Average Oral Concentration–Dose Relationships
- Index
- References
15 - Olanzapine and Olanzapine Pamoate
Published online by Cambridge University Press: 19 October 2021
Book contents
- The Clinical Use of Antipsychotic Plasma Levels
- Reviews
- The Clinical Use of Antipsychotic Plasma Levels
- Copyright page
- Half title page
- Contents
- Foreword
- Preface: How to Use This Handbook and Useful Tables for Handy Reference
- Introduction
- 1 Sampling Times for Oral and Long-Acting Injectable Agents
- 2 The Therapeutic Threshold and the Point of Futility
- 3 Level Interpretation Including Laboratory Reporting Issues, Responding to High Plasma Levels, Special Situations (Hepatic Dysfunction, Renal Dysfunction and Hemodialysis, Bariatric Surgery)
- 4 Tracking Oral Antipsychotic Adherence
- 5 What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability
- 6 Important Concepts about First-Generation Antipsychotics
- 7 Haloperidol and Haloperidol Decanoate
- 8 Fluphenazine and Fluphenazine Decanoate
- 9 Perphenazine and Perphenazine Decanoate
- 10 Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate
- 11 Chlorpromazine, Loxapine, Thiothixene, Trifluoperazine
- 12 Important Concepts about Second-Generation Antipsychotics
- 13 Clozapine
- 14 Risperidone Oral and Long-Acting Injectable; Paliperidone Oral and Long-Acting Injectable
- 15 Olanzapine and Olanzapine Pamoate
- 16 Aripiprazole, Aripiprazole Monohydrate, and Aripiprazole Lauroxil
- 17 Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine
- Appendix Therapeutic Threshold, Point of Futility, AGNP/ASCP Laboratory Alert Level, and Average Oral Concentration–Dose Relationships
- Index
- References
Summary
Olanzapine is among the more extensively studied second-generation antipsychotics (SGAs), partly due to its approval 25 years ago (1996), and also due to its penchant for significant metabolic adverse effects [9, 10]. Olanzapine distinguished itself by its efficacy profile (Figure 15.1), combined with lower rates of hyperprolactinemia and neurological adverse effects than first-generation antipsychotics (FGAs) and risperidone [11]. In the US Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, the primary outcome measure was time to all-cause discontinuation, and olanzapine outperformed other antipsychotics in phase 1 [12].
- Type
- Chapter
- Information
- The Clinical Use of Antipsychotic Plasma LevelsStahl's Handbooks, pp. 296 - 317Publisher: Cambridge University PressPrint publication year: 2021
References
Haslemo, T., Eikeseth, P. H., Tanum, L., et al. (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol, 62, 1049–1053.Google Scholar
Bishara, D., Olofinjana, O., Sparshatt, A., et al. (2013). Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol, 33, 329–335.Google Scholar
Perry, P. J., Lund, B. C., Sanger, T., et al. (2001). Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol, 21, 14–20.Google Scholar
Lu, M. L., Wu, Y. X., Chen, C. H., et al. (2016). Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor clinical efficacy in patients with schizophrenia. PLoS One, 11, e0148539.Google Scholar
Kelly, D. L., Richardson, C. M., Yang, Y., et al. (2006). Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol, 21, 393–398.Google Scholar
Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.Google Scholar
Bigos, K. L., Pollock, B. G., Coley, K. C., et al. (2008). Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol, 48, 157–165.Google Scholar
Patel, M. X., Bowskill, S., Couchman, L., et al. (2011). Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999–2009. J Clin Psychopharmacol, 31, 411–417.Google Scholar
Meyer, J. M., Davis, V. G., Goff, D. C., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res, 101, 273–286.Google Scholar
Meyer, J. M. (2010). Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci, 4, 23–42.Google Scholar
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 394, 939–951.Google Scholar
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.Google Scholar
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163, 600–610.Google Scholar
Pillinger, T., McCutcheon, R. A., Vano, L., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 7, 64–77.Google Scholar
Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar
Meltzer, H. Y., Bobo, W. V., Roy, A., et al. (2008). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry, 69, 274–285.Google Scholar
Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789–796.Google Scholar
Samara, M. T., Dold, M., Gianatsi, M., et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, 73, 199–210.Google Scholar
Howes, O. D., McCutcheon, R., Agid, O., et al. (2017). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174, 216–229.Google Scholar
Conley, R. R., Tamminga, C. A., Bartko, J. J., et al. (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry, 155, 914–920.Google Scholar
Conley, R. R., Tamminga, C. A., Kelly, D. L., et al. (1999). Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry, 46, 73–77.Google Scholar
Conley, R. R., Kelly, D. L., Richardson, C. M., et al. (2003). The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol, 23, 668–671.Google Scholar
Kahn, R. S., Winter, van Rossum, I., Leucht, S., et al. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry, 5, 797–807.Google Scholar
Detke, H. C., McDonnell, D. P., Brunner, E., et al. (2010). Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry, 10,Google Scholar
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar
Eli Lilly and Company (2020). Zyprexa Tablet, Intramuscular Injection package insert. Indianapolis, IN.Google Scholar
Soderberg, M. M. and Dahl, M. L. (2013). Pharmacogenetics of olanzapine metabolism. Pharmacogenomics, 14, 1319–1336.Google Scholar
Hiemke, C., Peled, A., Jabarin, M., et al. (2002). Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol, 22, 502–506.Google Scholar
Albers, L. J., Ozdemir, V., Marder, S. R., et al. (2005). Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol, 25, 170–174.Google Scholar
Khorassani, F., Kaufman, M., and Lopez, L. V. (2018). Supratherapeutic serum clozapine concentration after transition from traditional to electronic cigarettes. J Clin Psychopharmacol, 38, 391–392.Google Scholar
Patteet, L., Morrens, M., Maudens, K. E., et al. (2012). Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit, 34, 629–651.Google Scholar
Tveito, M., Smith, R. L., Høiseth, G., et al. (2019). The effect of valproic acid on olanzapine serum concentration: a study including 2791 patients treated with olanzapine tablets or long-acting injections. J Clin Psychopharmacol, 39, 561–566.Google Scholar
Food and Drug Administration Center for Drug Evaluation and Research (2003). Olanzapine for injection pharmacology/clinical pharmacology and biopharmaceutics review.Google Scholar
McDonnell, D. P., Detke, H. C., Bergstrom, R. F., et al. (2010). Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry, 10, 45–54.Google Scholar
Heres, S., Kraemer, S., Bergstrom, R. F., et al. (2014). Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol, 29, 299–312.Google Scholar
Detke, H. C., Zhao, F., Garhyan, P., et al. (2011). Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol, 26, 35–42.Google Scholar
Fellows, L., Ahmad, F., Castle, D. J., et al. (2003). Investigation of target plasma concentration–effect relationships for olanzapine in schizophrenia. Ther Drug Monit, 25, 682–689.Google Scholar
Leucht, S., Kane, J. M., Kissling, W., et al. (2005). What does the PANSS mean? Schizophr Res, 79, 231–238.Google Scholar
Mamo, D., Kapur, S., Keshavan, M., et al. (2008). D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology, 33, 298–304.Google Scholar
Lataster, J., van Os, J., de Haan, L., et al. (2011). Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J Clin Psychiatry, 72, 1397–1404.Google Scholar
Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol, 31, 318–325.Google Scholar
Mizuno, Y., Bies, R. R., Remington, G., et al. (2012). Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry, 37, 182–187.Google Scholar
Giegling, I., Drago, A., Schafer, M., et al. (2010). Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res, 44, 487–492.Google Scholar
de Haan, L., van Bruggen, M., Lavalaye, J., et al. (2003). Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry, 160, 303–309.Google Scholar
Veselinovicć, T., Scharpenberg, M., Heinze, M., et al. (2019). Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: results from the randomized NeSSy Trial. J Clin Psychopharmacol, 39, 550–560.Google Scholar
Kelly, D. L., Conley, R. R., Richardson, C. M., et al. (2003). Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry, 15, 181–186.Google Scholar
Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar